EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The MAO ‐B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti‐Androgen and Cytostatic Agents

Anita Steib, Krisztina Pohóczky, Norbert Tóth, Viktória Kormos, József Kun, Tamás Kálai, László Mangel, Péter Mátyus, Zsuzsanna Helyes iD

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Anita Steib und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacotherapy, Medical School & Centre for Neuroscience, University of Pécs, Pécs, Hungary. Hauptthemen laut MEDLINE: Selegiline, Monoamine Oxidase Inhibitors, Prostatic Neoplasms, Androgen Antagonists. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was funded by GINOP 2.2.1-15-2017-00067 provided for the project of Consortium of E-Group ICT Software Plc. and University of Pécs; National Laborat…, V.K. were supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00496/21/5, BO/00750/22/5), New National Excellence Program o…, Innovációs és Technológiai Minisztérium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current treatments for advanced prostate adenocarcinoma (PAC) include the androgen receptor antagonist enzalutamide and docetaxel‐based chemotherapy. Elevated monoamine oxidase‐A (MAO‐A) mRNA expression and activity in tumorous prostate positively correlate with disease progression and therapy resistance. While MAO‐B mRNA expression was also demonstrated in PAC cell lines, its role remained unclear. Therefore, this study evaluates the effects of the irreversible MAO‐B inhibitor selegiline and rasagiline and their combinations with conventional therapies on androgen‐insensitive (PC‐3, DU145) and androgen‐sensitive (22Rv1, LNCaP, VCaP) PAC cell lines. MAO activity was determined by the MAO‐Glo luminescence assay, viability by the ATP‐based chemiluminescence method, proliferation by the Luna‐II automated cell counter, and mRNA expressions by RT‐qPCR. MAO‐B mRNA was stably expressed by all PAC cell lines, with the highest expression in 22Rv1 and LNCaP cells. Selegiline reduced MAO‐B activity by 75%–80% and decreased cell counts by 40%–50% at 100 μM in PC‐3 and 22Rv1 cells. Selegiline concentration‐dependently inhibited cell proliferation (100 μM–10 mM) and reduced viability (1–10 mM) similar to rasagiline in all cell lines. Combination with enzalutamide in 22Rv1, and with docetaxel in PC‐3 demonstrated potentiating and additive effects, respectively. Selegiline reduced FOXA1 and GLUT1 mRNA expressions related to cancer progression and metabolism in both cell lines, increased the apoptosis‐related BAX in PC‐3, and decreased AR , EGFR , and SNAI2 in 22Rv1 linked to proliferation and metastasis. These findings suggest potential for selegiline repurposing in both androgen‐sensitive and ‐insensitive PAC therapy by promoting apoptosis and inhibiting cancer growth and survival signals, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SelegilineMonoamine Oxidase InhibitorsProstatic NeoplasmsAndrogen AntagonistsCytostatic AgentsHumansMaleCell Line, TumorCell SurvivalMonoamine OxidaseDocetaxelApoptosisCell ProliferationDrug SynergismNitrilesPhenylthiohydantoinBenzamidesIndans

Stichwörter der Autor:innen

anti‐androgen therapychemotherapydrug combinationmonoamine oxidaseprostate carcinomarepurposing

Substanzen

SelegilineMonoamine Oxidase InhibitorsMonoamine OxidaseAndrogen AntagonistsDocetaxelrasagilineNitrilesCytostatic AgentsenzalutamidePhenylthiohydantoin

Autor:innen und Institutionen

  • Department of Pharmacology and Pharmacotherapy, Medical School & Centre for Neuroscience, University of Pécs, Pécs, Hungary.
  • Eötvös Loránd Research Network, Chronic Pain Research Group, Pécs, Hungary.
  • Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Pécs, Hungary.
  • National Laboratory for Drug Research and Development, Budapest, Hungary.
  • Hungarian Centre for Genomics and Bioinformatics, Szentágothai Research Centre, University of Pécs, Pécs, Hungary.
  • Department of Organic and Pharmacological Chemistry, Faculty of Pharmacy, University of Pécs, Pécs, Hungary.

ORCID-Profile: Zsuzsanna Helyes

Förderung

  • This study was funded by GINOP 2.2.1-15-2017-00067 provided for the project of Consortium of E-Group ICT Software Plc. and University of Pécs; National Laborat…
  • V.K. were supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00496/21/5, BO/00750/22/5), New National Excellence Program o…
  • Innovációs és Technológiai Minisztérium

Zitieren

APA

Steib, A., Pohóczky, K., Tóth, N., Kormos, V., Kun, J., Kálai, T., Mangel, L., Mátyus, P., & Helyes, Z. (2025). The MAO ‐B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti‐Androgen and Cytostatic Agents. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70173

Vancouver

Steib A, Pohóczky K, Tóth N, Kormos V, Kun J, Kálai T, et al. The MAO ‐B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti‐Androgen and Cytostatic Agents. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70173

BibTeX
@article{Steib2025,
  author = {Steib, Anita and Pohóczky, Krisztina and Tóth, Norbert and Kormos, Viktória and Kun, József and Kálai, Tamás and Mangel, László and Mátyus, Péter and Helyes, Zsuzsanna},
  title = {The MAO ‐B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti‐Androgen and Cytostatic Agents},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70173}
}
Kostenlos starten →